<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649412</url>
  </required_header>
  <id_info>
    <org_study_id>209261</org_study_id>
    <secondary_id>2018-002370-48</secondary_id>
    <nct_id>NCT03649412</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772</brief_title>
  <official_title>A Two Part, Non-randomised, Open Label Study Designed to Assess the Pharmacokinetic Profile of Modified Release Prototype Coated Tablet Formulations of GSK2982772 Relative to an Immediate Release Reference Tablet Formulation at a Fixed Strength (Part A) and the Pharmacokinetic Profile of Alternative Tablet Strengths of the Selected Modified Release Prototype Coated Tablet Formulation (Part B, Optional) in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous clinical studies of immediate release (IR) formulations of GSK2982772 resulted in a
      high peak to trough ratio of GSK2982772. Additionally, the short half-life for GSK2982772
      (approximately 2 to 3 hours) necessitates twice a daily (BID) or thrice daily (TID) dosing of
      an IR formulation. As a result, MR formulations using a polymer matrix approach with
      minitablets in capsule and MR tablet formulations were investigated. The emerging PK data of
      the MR formulations investigated to date have demonstrated that a once daily (QD) PK profile
      can be achieved in the fasted state but the polymer matrix formulation is susceptible to food
      effects when administered with a high fat breakfast. The purpose of this study is to evaluate
      MR prototype coated tablet formulations. This study will evaluate the PK of MR prototype
      coated tablet formulations of GSK2982772. The study is divided into two parts; Part A and
      Part B. The MR tablet coating used in Part A and the initial periods of Part B will have an
      aperture drilled into the enteric coating of either side of the tablet. This allows some drug
      release to commence in the stomach whilst providing controlled release throughout the
      gastrointestinal (GI) tract. In Part B only, a new investigational medicinal product (IMP)
      will be manufactured to allow comparison of the tablet coating either with apertures (i.e.,
      drilled) or without apertures (i.e., full coat/non drilled). Part A will be a 6-period, 6-way
      fixed sequence design, up to 4 MR tablet prototype coated formulations will be evaluated in
      fasted state at 240 milligrams (mg). Periods 1, 2 and 3 will evaluate MR1, IR tablet and MR2
      respectively. Periods 4, 5 and 6 will be flexible and the dosing regimen will be dependent on
      the outcome of Periods 1 to 3. In addition, the impact of food (high fat meal, standard
      breakfast or administration 30 or 60 minutes before a standard breakfast) on selected MR
      prototype coated tablet formulations may also be evaluated in Period 4, 5 or 6 of Part A.
      Each inpatient period for MR regimens (Periods 1, 3, 4 to 6) will consist of 4 days and 3
      nights, and the inpatient period for the IR tablet (Period 2) will consist of 3 days and 2
      nights. There will be a minimum washout of 7 days between doses, and a follow-up visit will
      occur at 7 to 9 days after the last study treatment. The Part B of the study will be a
      7-period fixed sequence which will evaluate the selected MR prototype coated tablet
      formulation(s) at different tablet strengths or as multiple unit doses and with or without
      apertures in the tablet coatings. There will be an interim review after each period 1 to 5 of
      Part B to select the dose level, formulation and prandial status for each subsequent period.
      An interim data review after Part B Period 6 will determine if optional Period 7 is required
      and the dose level, dosing time (morning or evening), formulation and prandial status for
      that period. Each inpatient period will consist of a 4-day and 3-night with a minimum of 7
      days washout between doses. A follow-up visit will occur at 7 to 9 days after the last study
      treatment. Approximately 33 subjects will be enrolled in the study. The total duration for
      Part A will be approximately 10-12 weeks and 10-14 weeks for Part B (including screening
      period of approximately 4 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">May 7, 2019</completion_date>
  <primary_completion_date type="Actual">May 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A will be a 6-period, 6-way fixed sequence design, in which up to 4 MR tablet prototype coated formulation will be evaluated, following single dose administration (240 mg) in fasted or fed state. There will be a minimum 7-day washout between doses. Part B of the study is optional. Following the final period of Part A, there will be an interim review to determine whether to proceed with optional Part B, and if so, the formulations and tablet strengths to be investigated in Part B. The Part B of the study will be a 7-period fixed sequence which will evaluate the selected MR prototype coated tablet formulation(s) at different tablet strengths or as multiple unit doses.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>There will be no masking as this is an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 240 mg in IR Formulation</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis. PK parameters were analyzed using standard non-compartmental analysis. Participants in the 'Safety Population (all participants who received at least one dose of study treatment)' for whom a PK sample was obtained and analyzed were part of PK Population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC(0-inf) of GSK2982772 240 mg in MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points for PK analysis. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC(0-inf) of GSK2982772 240 mg in MR Coated Tablet Formulation After High-fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points for PK analysis. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 240 mg for IR Formulation</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC(0-t) of GSK2982772 240 mg for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC(0-t) of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 240 mg for IR Formulation</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC(0-24) of GSK2982772 240 mg for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC(0-24) of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Maximum Observed Concentration (Cmax) of GSK2982772 240 mg for IR Formulation</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cmax of GSK2982772 240 mg for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cmax of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Concentration at 24 Hours Post-dose (C24h) of GSK2982772 240 mg for IR Formulation</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: C24h of GSK2982772 240 mg for MR Coated Tablet Formulation</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: C24h of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Time to Cmax (Tmax) of GSK2982772 240 mg for IR Formulation</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Tmax of GSK2982772 240 mg for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Tmax of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Terminal Half-life (t1/2) of GSK2982772 240 mg for IR Formulation</measure>
    <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: t1/2 of GSK2982772 240 mg for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: t1/2 of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: AUC(0-inf) of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC(0-inf). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: AUC(0-t) of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC(0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Cmax of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: C24h of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Tmax of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: t1/2 of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Relative Bioavailability in Fed Versus Fasted Conditions (FrelFE) Based on AUC(0-inf) of GSK2982772 for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR Fed/ Geometric mean of AUC(0-inf) of MR Fasted multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: FrelFE Based on AUC(0-t) of GSK2982772 for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772. Frel for AUC(0-t) was calculated as Geometric mean of AUC(0-t) of MR Fed/Geometric mean of AUC(0-t) of MR Fasted multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: FrelFE Based on Cmax of GSK2982772 for MR Coated Tablet Formulation</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of FrelFE based on Cmax of GSK2982772. Frel for Cmax was calculated as Geometric mean of Cmax of MR Fed/Geometric mean of Cmax of MR Fasted multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: FrelFE of GSK2982772 Based on AUC(0-inf) for MR Coated Tablet Formulation in Fed vs Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC(0-inf) of GSK2982772. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR Fed/ Geometric mean of AUC(0-inf) of MR Fasted multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: FrelFE of GSK2982772 Based on AUC (0-t) for MR Coated Tablet Formulation in Fed vs Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC (0-t) of GSK2982772. FrelFE for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MR Fed/ Geometric mean of AUC (0-t) of MR Fasted multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: FrelFE of GSK2982772 Based on Cmax for MR Coated Tablet Formulation in Fed vs Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of FrelFE based on Cmax of GSK2982772. FrelFE for Cmax was calculated as Geometric mean of Cmax of MR Fed/ Geometric mean of Cmax of MR Fasted multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Frel of GSK2982772 Based on AUC (0-inf) for MR Coated Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC (0-inf) of GSK2982772. Frel (dose) for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MR formulation (test dose) Fasted/ Geometric mean of AUC (0-inf) of MR Fasted formulation (reference dose) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Frel of GSK2982772 Based on AUC (0-t) for MR Coated Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC(0-t) of GSK2982772. Frel (dose) for AUC(0-t) was calculated as Geometric mean of AUC(0-t) of MR formulation (test dose) Fasted/ Geometric mean of AUC(0-t) of MR Fasted formulation (reference dose) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Frel of GSK2982772 Based on AUC (0-24) for MR Coated Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC(0-24) of GSK2982772. Frel (dose) for AUC(0-24) was calculated as Geometric mean of AUC(0-24) of MR formulation (test dose) Fasted/Geometric mean of AUC(0-24) of MR Fasted formulation (reference dose) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Frel of GSK2982772 Based on Cmax for MR Coated Tablet Formulation in Fasted State</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frel dose. Frel for Cmax was calculated as Geometric mean of Cmax of MR formulation (test) Fasted/ Geometric mean of Cmax of MR Fasted Formulation (reference dose) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 240 mg</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC(0-inf) of GSK2982772 in fasted state. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR formulation (test) Fasted/ Geometric mean of AUC(0-inf) of Fasted of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Frelformulation Based on AUC (0-t) of GSK2982772 for MR Coated Tablet Formulation (240 mg)</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 in fasted state. Frel for AUC (0-t) was calculated as Geometric mean of AUC(0-t) of MR Fasted formulation (test) / Geometric mean of AUC(0-t) of Fasted of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Frelformulation Based on AUC(0-24) of GSK2982772 for MR Coated Tablet Formulation (240 mg)</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 in fasted state. Frel for AUC(0-24) was calculated as Geometric mean of AUC(0-24) of MR Fasted formulation (test) / Geometric mean of AUC(0-24) of Fasted of IR Formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Frelformulation Based on Cmax of GSK2982772 for MR Coated Tablet Formulation (240 mg)</measure>
    <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
    <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 in fasted state. Frel for Cmax was calculated as Geometric mean of Cmax of MR Fasted formulation (test) / Geometric mean of Cmax of Fasted Formulation of IR formulation (reference) multiplied by 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 67</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events that may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance (PCI) Criteria</measure>
    <time_frame>Up to Day 67</time_frame>
    <description>Clinical chemistry parameters with PCI values:albumin (low: &lt;30 millimoles per liter[mmol/L]), Alanine transaminase (ALT) (high: &gt;=2xupper limit of normal [ULN]), Aspartate Aminotransferase(AST) (high: &gt;=2xULN), Alkaline phosphatase(ALP) (high:&gt;=2xULN), calcium(low: &lt;2 mmol/L, high: &gt;2.75 mmol/L),creatinine (high: &gt;44.2 mmol/L),glucose (low: &lt;3 mmol/L,high: &gt;9 mmol/L), potassium (low: &lt;3 mmol/L,high: &gt;5.5 mmol/L),sodium (low: &lt;130 mmol/L,high: &gt;150 mmol/L),total bilirubin(high :&gt;= 1.5xULN). Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High),or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participants has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria</measure>
    <time_frame>Up to Day 67</time_frame>
    <description>Hematology parameters with PCI ranges: hematocrit (high: &gt;0.54 percentage of red blood cells), hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8*giga cells per liter [10^9/L]), total neutrophil count (low: &lt;1.5*10^9/L), platelet count (low: &lt;100*10^9/L and high: &gt;550*10^9/L), and while blood cell (WBC) count (low: &lt;3*10^9/L and high: &gt;20*10^9/L). Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of Participants With Abnormal Urinalysis Dipstick Results</measure>
    <time_frame>Day 2 (post-dose)</time_frame>
    <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed abnormal data for red blood cells (RBC): 1-9 High potential field (HPF) and WBC: 1-9/ HPF; WBC: 10-50/HPF has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in IR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
    <description>SBP and DBP were measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in SBP and DBP in MR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
    <description>SBP and DBP were measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Heart Rate in IR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
    <description>Heart rate was measured in a semi-supine position after 5 minutes of rest of participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Heart Rate in MR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
    <description>Heart rate was measured in a semi-supine position after 5 minutes of rest of participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Respiration Rate in IR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
    <description>Respiratory rate was measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Respiration Rate in MR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
    <description>Respiratory rate was measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Body Temperature in IR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
    <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change From Baseline in Body Temperature in MR Formulation</measure>
    <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
    <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in IR Formulation</measure>
    <time_frame>Up to Day 67</time_frame>
    <description>Single 12-lead ECGs were obtained using an automated ECG machine that calculated PR, QRS, QT and Corrected QT (QTc) intervals. ECG measurements were performed in a semi-supine or supine position. Number of participants with abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in MR Formulation</measure>
    <time_frame>Up to Day 67</time_frame>
    <description>Single 12-lead ECGs were obtained using an automated ECG machine that calculated PR, QRS, QT and Corrected QT (QTc) intervals. ECG measurements were performed in a semi-supine or supine position. Number of participants with abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for worst-case post-Baseline has been reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Subjects in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Part B will receive GSK2982772 MR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2982772 Modified Release</intervention_name>
    <description>GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.</description>
    <arm_group_label>Subjects in Part A</arm_group_label>
    <arm_group_label>Subjects in Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2982772 Immediate Release</intervention_name>
    <description>In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water</description>
    <arm_group_label>Subjects in Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject at the time of participation must be 18 to 65 years of age.

          -  Subjects who are overtly healthy as determined by medical evaluation including medical
             history, physical examination, laboratory tests, and cardiac monitoring.

          -  Body weight greater than or equal to 50 kilogram (kg) and body mass index within the
             range 19.0 to 32.0 kg per squared meter (kg/m^2) (inclusive).

          -  Male or female subjects where male subjects are eligible to participate if they agree
             to the following during the intervention period until completion of the final follow
             up visit after the last dose of study treatment; refrain from sperm donation; plus
             either be abstinent from heterosexual or homosexual intercourse as their preferred and
             usual lifestyle (abstinent on a long term and persistent basis) and agree to remain
             abstinent; or must agree to use contraception/barrier like use a male condom and
             should also be advised of the benefit for a female partner to use a highly effective
             method of contraception as a condom may break or leak when having sexual intercourse
             with a woman of childbearing potential who is not currently pregnant; agree to use
             male condom when engaging in any activity that allows for passage of ejaculate to
             another person.

          -  The eligible female subjects can participate if she is not pregnant or breastfeeding,
             and at least one of the following conditions applies: is not a woman of childbearing
             potential (WOCBP); is a WOCBP and using a contraceptive method that is highly
             effective (with a failure rate of less than 1 percentage per year), preferably with
             low user dependency, for at least 30 days before first dose until completion of the
             final follow up visit after the last dose of study treatment and agrees not to donate
             eggs (ova, oocytes) for the purpose of reproduction from Day 1 until 3 months after
             the last dose. The investigator should evaluate the effectiveness of the contraceptive
             method in relationship to the first dose of study intervention; a WOCBP must have a
             negative highly sensitive serum pregnancy test within 24 hours before the first dose
             of study intervention; additional requirements for pregnancy testing during and after
             study intervention must be followed; the investigator is responsible for review of
             medical history, menstrual history, and recent sexual activity to decrease the risk
             for inclusion of a woman with an early undetected pregnancy.

          -  Capable of giving an Informed Consent.

        Exclusion Criteria:

          -  History of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal
             (GI), endocrine, hematological, or neurological disorders capable of significantly
             altering the absorption, metabolism, or elimination of drugs; constituting a risk when
             taking the study treatment; or interfering with the interpretation of data.

          -  Any history of suicidal behavior within the past 6 months or any history of attempted
             suicide in subject's lifetime.

          -  History of clinically significant psychiatric disorders as judged by the investigator.
             Depression requiring treatment in the last 2 years.

          -  History of herpes zoster (shingles) reactivation.

          -  History or diagnosis of obstructive Sleep Apnea.

          -  History of a significant respiratory disorder. Childhood asthma that has fully
             resolved is permitted.

          -  History or current evidence of febrile seizures, epilepsy, convulsions, significant
             head injury, or other significant neurologic conditions.

          -  A positive diagnostic tuberculosis (TB) test at screening defined as a positive
             QuantiFERON-TB Gold test or T-spot test. In cases where the QuantiFERON or T-spot test
             is indeterminate, the subject may have the test repeated once, but they will not be
             eligible for the study unless the second test is negative.

          -  History of GI surgery (with exception of appendectomy).

          -  History of cholecystectomy or gall stones.

          -  Presence or history of clinically significant allergy requiring treatment, as judged
             by the investigator. Hayfever is allowed unless it is active.

          -  Alanine transaminase (ALT) greater than 1.5 times upper limit of normal (ULN).

          -  Bilirubin greater than 1.5 times ULN (isolated bilirubin greater than 1.5 times ULN is
             acceptable if bilirubin is fractionated and direct bilirubin less than 35 percentage
             of total).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome).

          -  Corrected QT interval (QTcF) greater than 450 milliseconds (msec).

          -  Past or intended use of over-the-counter or prescription medication including herbal
             medications within 7 days prior to dosing (paracetamol/acetaminophen [up to 2 gram per
             day], hormone replacement therapy and hormonal contraception are permitted).

          -  Live or attenuated vaccine(s) within 30 days of enrolment, or plans to receive such
             vaccines during the study or plans to receive a vaccine within 30 days plus 5 half
             lives, of the last dose of study medication.

          -  Participation in the study would result in loss of blood or blood products in excess
             of 500 mL within a 56 day period; therefore donation or loss of greater than 400 mL of
             blood within the previous 3 months.

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  Current enrolment or past participation within the last 3 months before signing of
             consent in this or any other clinical study involving an investigational study
             treatment or any other type of medical research.

          -  Subjects who have previously been enrolled in this study. Subjects in Part A of this
             study are not permitted to participate in Part B.

          -  Current or history of renal disease or estimated glomerular filtration rate by chronic
             kidney disease epidemiology collaboration (CKD-EPI) equation calculation less than 60
             milliliter (mL) per minute per 1.73 m^2 at screening.

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening. Positive Hepatitis C
             antibody test result at screening or within 3 months prior to first dose. As potential
             for and magnitude of immunosuppression with this compound is unknown, subjects with
             presence of Hepatitis B core antibody (HBcAb) should be excluded. Subjects positive
             for HBsAg and/or positive for anti-HBc antibody (regardless of anti-HBs antibody
             status) are excluded.

          -  An elevated C-reactive protein (CRP) outside the normal reference range.

          -  Confirmed positive pre-study drug/alcohol screen.

          -  Positive human immunodeficiency virus (HIV) antibody test.

          -  Regular use of known drugs of abuse, or history of drug or alcohol abuse in the past 5
             years.

          -  Regular alcohol consumption within 6 months prior to the study defined as an average
             weekly intake of greater than 21 units for males or greater than14 units for females.
             One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 mL) of
             beer or 1 (25 mL) measure of spirits, 1.5 to 2 units is 1 glass (125 mL) of wine,
             depending on type.

          -  Current use or history of regular use of tobacco- or nicotine-containing products
             within 6 months prior to screening. A carbon monoxide breath test reading of greater
             than 10 parts per million (ppm).

          -  Sensitivity to any of the study treatments, or components thereof, or drug or other
             allergy that, in the opinion of the investigator or medical monitor, contraindicates
             participation in the study.

          -  Subjects who do not have suitable veins for multiple venipuncture's/cannulation as
             assessed by the investigator at screening.

          -  Total cholesterol greater than or equal to 300 mg per deciliter (mg/dL) (greater than
             or equal to 7.77 millimole per liter [mmol]/L]) or triglycerides greater than or equal
             to 250 mg/dL (greater than or equal to 2.82 mmol/L).

          -  Subjects who are study site or sponsor employees, or immediate family members of a
             study site or sponsor employee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <results_first_submitted>April 8, 2020</results_first_submitted>
  <results_first_submitted_qc>April 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2020</results_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tablet formulation</keyword>
  <keyword>Sequence</keyword>
  <keyword>Immediate release</keyword>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available, within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided, after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided, for an initial period of 12 months but an extension can be granted, when justified for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03649412/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03649412/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an open-label, 2-part (Part A &amp; B), single dose study in healthy participants to assess modified release (MR) prototype coated tablet formulations of GSK2982772 compared to an immediate release reference tablet formulation.</recruitment_details>
      <pre_assignment_details>A total of 33 participants were enrolled in this study. In Part A, 16 participants were enrolled but 1 replacement participant was added (total=17). Participants from Part A did not continue to Part B. In Part B, 16 participants were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MR 12h Fast/IR Fast/MR18h Fast/MR 18h Fed/MR 12h Fed/MR16hFast</title>
          <description>Participants in Part A received a single dose of 240 milligrams (mg) GSK2982772 MR-12 hour (h) tablet (80 percent [%] release in 12 hours) in fasted (fast) state in Period 1 followed by a single dose of GSK2982772 240 mg (8x30mg) immediate release (IR) tablet in fasted state in Period 2 followed by a single dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fasted state in Period 3. In Period 4, participants received a single dose of 240 mg GSK2982772 MR-18h tablet after a high-fat meal (fed state) followed by a single dose of MR-12h tablet after a high fat meal (fed state) in Period 5. In Period 6, participants received a single dose of 240 mg of GSK2982772 of MR-16h tablet (80% release in 16 hours) in a fasted state. There was a washout of 7 days between each treatment period. All doses were administered orally with 240 milliliters (mL) of water.</description>
        </group>
        <group group_id="P2">
          <title>MR 480Fast/960Fast/480Fed/120Fast/480 Fed (Ent)/480 Fed(Std)</title>
          <description>Participants in Part B received a single dose of 480 mg GSK2982772 MR-16h tablet (80% release in 16 hours) in a fasted state in Period 1 followed by a single dose 960 mg GSK2982772 MR-16h tablet in a fasted state in Period 2 followed by a single dose of 480 mg GSK2982772 MR-16h tablet after a high-fat meal (fed state) in Period 3. In Period 4, participants received a single dose of 120 mg GSK2982772 MR-16h tablet in a fasted state followed by a single dose of 480 mg GSK2982772 MR-16h enteric (Ent) coated tablet after a high-fat meal (fed state) in Period 5. In Period 6, participants received a single dose of 480 mg GSK2982772 MR-16h tablet after a standard meal (fed state).There was a washout of 7 days between each treatment period. All doses were administered orally with 240 mL of water.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A, Period 1 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A, Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A, Period 2 (3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">1 Replacement par. was enrolled &amp; dosed</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A, Washout Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A, Period 3 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A, Washout Period 3 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A, Period 4 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A, Washout Period 4 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A, Period 5 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">Two participant did not start in Period 5</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part A, Washout Period 5 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part A, Period 6 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">1 of the participant who did not start Period 5 directly joined into Period 6</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Period 1 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants in Part A did not enter Part B</participants>
                <participants group_id="P2" count="16">16 new participants enrolled in Part B</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B, Period 2 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Washout Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Period 3 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Washout Period 3 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Period 4 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Washout Period 4 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Period 5 (4 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14">One participant did not start in Period 5</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B, Washout Period 5 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B, Period 6 (4days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14">Participant who did not start Period 5 directly joined into Period 6</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MR 12h Fast/IR Fast/MR18h Fast/MR 18h Fed/MR 12h Fed/MR16hFast</title>
          <description>Participants in Part A received a single dose of 240 milligrams (mg) GSK2982772 MR-12 hour (h) tablet (80 percent [%] release in 12 hours) in fasted (fast) state in Period 1 followed by a single dose of GSK2982772 240 mg (8x30mg) immediate release (IR) tablet in fasted state in Period 2 followed by a single dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fasted state in Period 3. In Period 4, participants received a single dose of 240 mg GSK2982772 MR-18h tablet after a high-fat meal (fed state) followed by a single dose of MR-12h tablet after a high fat meal (fed state) in Period 5. In Period 6, participants received a single dose of 240 mg of GSK2982772 of MR-16h tablet (80% release in 16 hours) in a fasted state. There was a washout of 7 days between each treatment period. All doses were administered orally with 240 milliliters (mL) of water.</description>
        </group>
        <group group_id="B2">
          <title>MR 480Fast/960Fast/480Fed/120Fast/480 Fed (Ent)/480 Fed(Std)</title>
          <description>Participants in Part B received a single dose of 480 mg GSK2982772 MR-16h tablet (80% release in 16 hours) in a fasted state in Period 1 followed by a single dose 960 mg GSK2982772 MR-16h tablet in a fasted state in Period 2 followed by a single dose of 480 mg GSK2982772 MR-16h tablet after a high-fat meal (fed state) in Period 3. In Period 4, participants received a single dose of 120 mg GSK2982772 MR-16h tablet in a fasted state followed by a single dose of 480 mg GSK2982772 MR-16h enteric (Ent) coated tablet after a high-fat meal (fed state) in Period 5. In Period 6, participants received a single dose of 480 mg GSK2982772 MR-16h tablet after a standard meal (fed state).There was a washout of 7 days between each treatment period. All doses were administered orally with 240 mL of water.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="12.17"/>
                    <measurement group_id="B2" value="54.0" spread="6.30"/>
                    <measurement group_id="B3" value="48.6" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ARABIC/NORTH AFRICAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>WHITE/CAUCASIAN/EUROPEAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AFRICAN AMERICAN/AFRICAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>CENTRAL/SOUTH ASIAN HERITAGE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MULTIPLE</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 240 mg in IR Formulation</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis. PK parameters were analyzed using standard non-compartmental analysis. Participants in the 'Safety Population (all participants who received at least one dose of study treatment)' for whom a PK sample was obtained and analyzed were part of PK Population.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 240 mg in IR Formulation</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis. PK parameters were analyzed using standard non-compartmental analysis. Participants in the 'Safety Population (all participants who received at least one dose of study treatment)' for whom a PK sample was obtained and analyzed were part of PK Population.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.355" spread="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC(0-inf) of GSK2982772 240 mg in MR Coated Tablet Formulation</title>
        <description>Blood samples were collected from participants at indicated time points for PK analysis. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC(0-inf) of GSK2982772 240 mg in MR Coated Tablet Formulation</title>
          <description>Blood samples were collected from participants at indicated time points for PK analysis. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.757" spread="19.1"/>
                    <measurement group_id="O2" value="8.346" spread="27.7"/>
                    <measurement group_id="O3" value="7.080" spread="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC(0-inf) of GSK2982772 240 mg in MR Coated Tablet Formulation After High-fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points for PK analysis. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC(0-inf) of GSK2982772 240 mg in MR Coated Tablet Formulation After High-fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points for PK analysis. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.372" spread="21.8"/>
                    <measurement group_id="O2" value="8.220" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 240 mg for IR Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 240 mg for IR Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.269" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC(0-t) of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC(0-t) of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.175" spread="23.9"/>
                    <measurement group_id="O2" value="7.828" spread="28.5"/>
                    <measurement group_id="O3" value="7.365" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC(0-t) of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC(0-t) of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.359" spread="23.1"/>
                    <measurement group_id="O2" value="8.384" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 240 mg for IR Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 240 mg for IR Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.268" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC(0-24) of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC(0-24) of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.670" spread="24.9"/>
                    <measurement group_id="O2" value="5.784" spread="31.8"/>
                    <measurement group_id="O3" value="5.466" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC(0-24) of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC(0-24) of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.136" spread="33.5"/>
                    <measurement group_id="O2" value="5.821" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Maximum Observed Concentration (Cmax) of GSK2982772 240 mg for IR Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Maximum Observed Concentration (Cmax) of GSK2982772 240 mg for IR Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.177" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Cmax of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Cmax of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.682" spread="39.4"/>
                    <measurement group_id="O2" value="0.527" spread="24.4"/>
                    <measurement group_id="O3" value="0.466" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Cmax of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Cmax of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.824" spread="47.5"/>
                    <measurement group_id="O2" value="0.678" spread="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Concentration at 24 Hours Post-dose (C24h) of GSK2982772 240 mg for IR Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Concentration at 24 Hours Post-dose (C24h) of GSK2982772 240 mg for IR Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="60.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: C24h of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: C24h of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.196" spread="64.8"/>
                    <measurement group_id="O2" value="0.211" spread="63.1"/>
                    <measurement group_id="O3" value="0.165" spread="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: C24h of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: C24h of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.213" spread="70.4"/>
                    <measurement group_id="O2" value="0.265" spread="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Time to Cmax (Tmax) of GSK2982772 240 mg for IR Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Time to Cmax (Tmax) of GSK2982772 240 mg for IR Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="1.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Tmax of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Tmax of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.000" lower_limit="4.00" upper_limit="12.03"/>
                    <measurement group_id="O2" value="10.000" lower_limit="4.00" upper_limit="24.20"/>
                    <measurement group_id="O3" value="6.000" lower_limit="4.00" upper_limit="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Tmax of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Tmax of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="2.00" upper_limit="22.00"/>
                    <measurement group_id="O2" value="11.000" lower_limit="8.00" upper_limit="22.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Terminal Half-life (t1/2) of GSK2982772 240 mg for IR Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Terminal Half-life (t1/2) of GSK2982772 240 mg for IR Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.288" spread="0.5010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: t1/2 of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: t1/2 of GSK2982772 240 mg for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.329" spread="2.1447"/>
                    <measurement group_id="O2" value="6.953" spread="2.4983"/>
                    <measurement group_id="O3" value="7.532" spread="2.2685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: t1/2 of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: t1/2 of GSK2982772 240 mg for MR Coated Tablet Formulation After High-fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.763" spread="1.4693"/>
                    <measurement group_id="O2" value="6.589" spread="1.0499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: AUC(0-inf) of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC(0-inf). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (High-Fat) (Enteric Coated)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) enteric coated tablet after a high fat breakfast (fed state)</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: AUC(0-inf) of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC(0-inf). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.121" spread="46.2"/>
                    <measurement group_id="O2" value="20.178" spread="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: AUC(0-t) of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC(0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (High-Fat) (Enteric Coated)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) enteric coated tablet after a high fat breakfast (fed state)</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: AUC(0-t) of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC(0-t). PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.865" spread="39.7"/>
                    <measurement group_id="O2" value="17.861" spread="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Cmax of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (High-Fat) (Enteric Coated)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) enteric coated tablet after a high fat breakfast (fed state)</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Cmax of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.896" spread="63.3"/>
                    <measurement group_id="O2" value="1.791" spread="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: C24h of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (High-Fat) (Enteric Coated)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) enteric coated tablet after a high fat breakfast (fed state)</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: C24h of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for C24h. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.622" spread="132.9"/>
                    <measurement group_id="O2" value="1.176" spread="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Tmax of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (High-Fat) (Enteric Coated)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) enteric coated tablet after a high fat breakfast (fed state)</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Tmax of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Tmax. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.000" lower_limit="6.00" upper_limit="28.00"/>
                    <measurement group_id="O2" value="22.008" lower_limit="10.00" upper_limit="24.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: t1/2 of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast (fed state)</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (High-Fat) (Enteric Coated)</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) enteric coated tablet after a high fat breakfast (fed state)</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: t1/2 of GSK2982772 for MR Coated Tablet Formulation After a High Fat Breakfast</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for t1/2. PK parameters were analyzed using standard non-compartmental analysis.</description>
          <population>PK Population. Only those participants with data available at specified time point were analyzed.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.961" spread="1.0921"/>
                    <measurement group_id="O2" value="4.873" spread="1.9915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Relative Bioavailability in Fed Versus Fasted Conditions (FrelFE) Based on AUC(0-inf) of GSK2982772 for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR Fed/ Geometric mean of AUC(0-inf) of MR Fasted multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-18h 240mg Fed and MR-18h 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fed (high-fat) state and received MR-18h (80% release in 18 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-12h 240mg Fed and MR-12h 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h (80% release in 12 hours) tablet in fed (high-fat) state and received MR-12h (80% release in 12 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Relative Bioavailability in Fed Versus Fasted Conditions (FrelFE) Based on AUC(0-inf) of GSK2982772 for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR Fed/ Geometric mean of AUC(0-inf) of MR Fasted multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.66" lower_limit="88.84" upper_limit="118.63"/>
                    <measurement group_id="O2" value="113.66" lower_limit="95.53" upper_limit="135.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: FrelFE Based on AUC(0-t) of GSK2982772 for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772. Frel for AUC(0-t) was calculated as Geometric mean of AUC(0-t) of MR Fed/Geometric mean of AUC(0-t) of MR Fasted multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-18h 240mg Fed and MR-18h 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fed (high-fat) state and received MR-18h (80% release in 18 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-12h 240mg Fed and MR-12h 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h (80% release in 12 hours) tablet in fed (high-fat) state and received MR-12h (80% release in 12 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: FrelFE Based on AUC(0-t) of GSK2982772 for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772. Frel for AUC(0-t) was calculated as Geometric mean of AUC(0-t) of MR Fed/Geometric mean of AUC(0-t) of MR Fasted multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.11" lower_limit="95.72" upper_limit="119.85"/>
                    <measurement group_id="O2" value="107.81" lower_limit="95.16" upper_limit="122.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: FrelFE Based on Cmax of GSK2982772 for MR Coated Tablet Formulation</title>
        <description>Blood samples were collected at indicated time points for analysis of FrelFE based on Cmax of GSK2982772. Frel for Cmax was calculated as Geometric mean of Cmax of MR Fed/Geometric mean of Cmax of MR Fasted multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-18h 240mg Fed and MR-18h 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fed (high-fat) state and received MR-18h (80% release in 18 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-12h 240mg Fed and MR-12h 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h (80% release in 12 hours) tablet in fed (high-fat) state and received MR-12h (80% release in 12 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: FrelFE Based on Cmax of GSK2982772 for MR Coated Tablet Formulation</title>
          <description>Blood samples were collected at indicated time points for analysis of FrelFE based on Cmax of GSK2982772. Frel for Cmax was calculated as Geometric mean of Cmax of MR Fed/Geometric mean of Cmax of MR Fasted multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.79" lower_limit="108.64" upper_limit="152.67"/>
                    <measurement group_id="O2" value="112.15" lower_limit="92.90" upper_limit="135.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: FrelFE of GSK2982772 Based on AUC(0-inf) for MR Coated Tablet Formulation in Fed vs Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC(0-inf) of GSK2982772. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR Fed/ Geometric mean of AUC(0-inf) of MR Fasted multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-fat) and MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast in fed state and received a single oral dose of 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (Standard) and MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after a standard breakfast in fed state and received a single oral dose of 480mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: FrelFE of GSK2982772 Based on AUC(0-inf) for MR Coated Tablet Formulation in Fed vs Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC(0-inf) of GSK2982772. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR Fed/ Geometric mean of AUC(0-inf) of MR Fasted multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at specified time frame were analyzed.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.75" lower_limit="113.47" upper_limit="177.07"/>
                    <measurement group_id="O2" value="97.13" lower_limit="78.47" upper_limit="120.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: FrelFE of GSK2982772 Based on AUC (0-t) for MR Coated Tablet Formulation in Fed vs Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC (0-t) of GSK2982772. FrelFE for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MR Fed/ Geometric mean of AUC (0-t) of MR Fasted multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-fat) and MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast in fed state and received a single oral dose of 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (Standard) and MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after a standard breakfast in fed state and received a single oral dose of 480mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: FrelFE of GSK2982772 Based on AUC (0-t) for MR Coated Tablet Formulation in Fed vs Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of FrelFE based on AUC (0-t) of GSK2982772. FrelFE for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MR Fed/ Geometric mean of AUC (0-t) of MR Fasted multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.63" lower_limit="109.23" upper_limit="153.83"/>
                    <measurement group_id="O2" value="89.77" lower_limit="75.37" upper_limit="106.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: FrelFE of GSK2982772 Based on Cmax for MR Coated Tablet Formulation in Fed vs Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of FrelFE based on Cmax of GSK2982772. FrelFE for Cmax was calculated as Geometric mean of Cmax of MR Fed/ Geometric mean of Cmax of MR Fasted multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 480mg Fed (High-fat) vs MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast in fed state and received a single oral dose of 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 480mg Fed (Standard) and MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after a standard breakfast in fed state and received a single oral dose of 480mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: FrelFE of GSK2982772 Based on Cmax for MR Coated Tablet Formulation in Fed vs Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of FrelFE based on Cmax of GSK2982772. FrelFE for Cmax was calculated as Geometric mean of Cmax of MR Fed/ Geometric mean of Cmax of MR Fasted multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.19" lower_limit="138.68" upper_limit="216.28"/>
                    <measurement group_id="O2" value="102.39" lower_limit="81.61" upper_limit="128.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Frel of GSK2982772 Based on AUC (0-inf) for MR Coated Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC (0-inf) of GSK2982772. Frel (dose) for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MR formulation (test dose) Fasted/ Geometric mean of AUC (0-inf) of MR Fasted formulation (reference dose) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 960mg Fasted and MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 960mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part B: MR-16h 480mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Frel of GSK2982772 Based on AUC (0-inf) for MR Coated Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC (0-inf) of GSK2982772. Frel (dose) for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MR formulation (test dose) Fasted/ Geometric mean of AUC (0-inf) of MR Fasted formulation (reference dose) multiplied by 100.</description>
          <population>PK Population. Only those participants with data available at specified time points were analyzed.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.21" lower_limit="171.24" upper_limit="267.95"/>
                    <measurement group_id="O2" value="530.86" lower_limit="431.89" upper_limit="652.49"/>
                    <measurement group_id="O3" value="247.82" lower_limit="201.70" upper_limit="304.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Frel of GSK2982772 Based on AUC (0-t) for MR Coated Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC(0-t) of GSK2982772. Frel (dose) for AUC(0-t) was calculated as Geometric mean of AUC(0-t) of MR formulation (test dose) Fasted/ Geometric mean of AUC(0-t) of MR Fasted formulation (reference dose) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 960mg Fasted vs MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 960mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part B: MR-16h 480mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Frel of GSK2982772 Based on AUC (0-t) for MR Coated Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC(0-t) of GSK2982772. Frel (dose) for AUC(0-t) was calculated as Geometric mean of AUC(0-t) of MR formulation (test dose) Fasted/ Geometric mean of AUC(0-t) of MR Fasted formulation (reference dose) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.81" lower_limit="162.47" upper_limit="228.80"/>
                    <measurement group_id="O2" value="539.66" lower_limit="454.37" upper_limit="640.96"/>
                    <measurement group_id="O3" value="279.90" lower_limit="235.86" upper_limit="332.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Frel of GSK2982772 Based on AUC (0-24) for MR Coated Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC(0-24) of GSK2982772. Frel (dose) for AUC(0-24) was calculated as Geometric mean of AUC(0-24) of MR formulation (test dose) Fasted/Geometric mean of AUC(0-24) of MR Fasted formulation (reference dose) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 960mg Fasted vs MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 960mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part B: MR-16h 480mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Frel of GSK2982772 Based on AUC (0-24) for MR Coated Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Frel (dose) based on AUC(0-24) of GSK2982772. Frel (dose) for AUC(0-24) was calculated as Geometric mean of AUC(0-24) of MR formulation (test dose) Fasted/Geometric mean of AUC(0-24) of MR Fasted formulation (reference dose) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.58" lower_limit="143.34" upper_limit="215.08"/>
                    <measurement group_id="O2" value="392.65" lower_limit="320.16" upper_limit="481.54"/>
                    <measurement group_id="O3" value="223.63" lower_limit="182.56" upper_limit="273.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Frel of GSK2982772 Based on Cmax for MR Coated Tablet Formulation in Fasted State</title>
        <description>Blood samples were collected at indicated time points for analysis of Frel dose. Frel for Cmax was calculated as Geometric mean of Cmax of MR formulation (test) Fasted/ Geometric mean of Cmax of MR Fasted Formulation (reference dose) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: MR-16h 960mg Fasted vs MR-16h 480mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part B: MR-16h 960mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part B: MR-16h 480mg Fasted vs MR-16h 120mg Fasted</title>
            <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Frel of GSK2982772 Based on Cmax for MR Coated Tablet Formulation in Fasted State</title>
          <description>Blood samples were collected at indicated time points for analysis of Frel dose. Frel for Cmax was calculated as Geometric mean of Cmax of MR formulation (test) Fasted/ Geometric mean of Cmax of MR Fasted Formulation (reference dose) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.00" lower_limit="128.12" upper_limit="199.81"/>
                    <measurement group_id="O2" value="338.70" lower_limit="270.88" upper_limit="423.89"/>
                    <measurement group_id="O3" value="211.68" lower_limit="169.51" upper_limit="264.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 240 mg</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC(0-inf) of GSK2982772 in fasted state. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR formulation (test) Fasted/ Geometric mean of AUC(0-inf) of Fasted of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h (80% release in 12 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-16h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received a single oral dsoe of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 240 mg</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC(0-inf) of GSK2982772 in fasted state. Frel for AUC(0-inf) was calculated as Geometric mean of AUC(0-inf) of MR formulation (test) Fasted/ Geometric mean of AUC(0-inf) of Fasted of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.68" lower_limit="47.64" upper_limit="62.76"/>
                    <measurement group_id="O2" value="48.32" lower_limit="40.96" upper_limit="57.01"/>
                    <measurement group_id="O3" value="57.69" lower_limit="50.58" upper_limit="65.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Frelformulation Based on AUC (0-t) of GSK2982772 for MR Coated Tablet Formulation (240 mg)</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 in fasted state. Frel for AUC (0-t) was calculated as Geometric mean of AUC(0-t) of MR Fasted formulation (test) / Geometric mean of AUC(0-t) of Fasted of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h (80% release in 12 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-16h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received a single oral dsoe of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Frelformulation Based on AUC (0-t) of GSK2982772 for MR Coated Tablet Formulation (240 mg)</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 in fasted state. Frel for AUC (0-t) was calculated as Geometric mean of AUC(0-t) of MR Fasted formulation (test) / Geometric mean of AUC(0-t) of Fasted of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.72" lower_limit="51.51" upper_limit="64.69"/>
                    <measurement group_id="O2" value="49.61" lower_limit="43.86" upper_limit="56.11"/>
                    <measurement group_id="O3" value="54.86" lower_limit="49.03" upper_limit="61.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Frelformulation Based on AUC(0-24) of GSK2982772 for MR Coated Tablet Formulation (240 mg)</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 in fasted state. Frel for AUC(0-24) was calculated as Geometric mean of AUC(0-24) of MR Fasted formulation (test) / Geometric mean of AUC(0-24) of Fasted of IR Formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h (80% release in 12 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-16h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received a single oral dsoe of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Frelformulation Based on AUC(0-24) of GSK2982772 for MR Coated Tablet Formulation (240 mg)</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 in fasted state. Frel for AUC(0-24) was calculated as Geometric mean of AUC(0-24) of MR Fasted formulation (test) / Geometric mean of AUC(0-24) of Fasted of IR Formulation (reference) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.77" lower_limit="41.92" upper_limit="54.43"/>
                    <measurement group_id="O2" value="36.85" lower_limit="31.99" upper_limit="42.45"/>
                    <measurement group_id="O3" value="40.54" lower_limit="35.63" upper_limit="46.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: Frelformulation Based on Cmax of GSK2982772 for MR Coated Tablet Formulation (240 mg)</title>
        <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 in fasted state. Frel for Cmax was calculated as Geometric mean of Cmax of MR Fasted formulation (test) / Geometric mean of Cmax of Fasted Formulation of IR formulation (reference) multiplied by 100.</description>
        <time_frame>Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36 and 48 hours</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h (80% release in 12 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-16h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state and received a single oral dsoe of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240mg Fasted and IR 240mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h (80% release in 18 hours) tablet in fasted state and received a single oral dose of 240 mg GSK2982772 IR tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Frelformulation Based on Cmax of GSK2982772 for MR Coated Tablet Formulation (240 mg)</title>
          <description>Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 in fasted state. Frel for Cmax was calculated as Geometric mean of Cmax of MR Fasted formulation (test) / Geometric mean of Cmax of Fasted Formulation of IR formulation (reference) multiplied by 100.</description>
          <population>PK Population.</population>
          <units>Percentage bioavailability</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.29" lower_limit="18.77" upper_limit="26.47"/>
                    <measurement group_id="O2" value="14.16" lower_limit="11.75" upper_limit="17.06"/>
                    <measurement group_id="O3" value="16.58" lower_limit="13.99" upper_limit="19.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events that may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
        <time_frame>Up to Day 67</time_frame>
        <population>Safety Population consisted of all participants who receive at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O6">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events that may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.</description>
          <population>Safety Population consisted of all participants who receive at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance (PCI) Criteria</title>
        <description>Clinical chemistry parameters with PCI values:albumin (low: &lt;30 millimoles per liter[mmol/L]), Alanine transaminase (ALT) (high: &gt;=2xupper limit of normal [ULN]), Aspartate Aminotransferase(AST) (high: &gt;=2xULN), Alkaline phosphatase(ALP) (high:&gt;=2xULN), calcium(low: &lt;2 mmol/L, high: &gt;2.75 mmol/L),creatinine (high: &gt;44.2 mmol/L),glucose (low: &lt;3 mmol/L,high: &gt;9 mmol/L), potassium (low: &lt;3 mmol/L,high: &gt;5.5 mmol/L),sodium (low: &lt;130 mmol/L,high: &gt;150 mmol/L),total bilirubin(high :&gt;= 1.5xULN). Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High),or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participants has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 67</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O6">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance (PCI) Criteria</title>
          <description>Clinical chemistry parameters with PCI values:albumin (low: &lt;30 millimoles per liter[mmol/L]), Alanine transaminase (ALT) (high: &gt;=2xupper limit of normal [ULN]), Aspartate Aminotransferase(AST) (high: &gt;=2xULN), Alkaline phosphatase(ALP) (high:&gt;=2xULN), calcium(low: &lt;2 mmol/L, high: &gt;2.75 mmol/L),creatinine (high: &gt;44.2 mmol/L),glucose (low: &lt;3 mmol/L,high: &gt;9 mmol/L), potassium (low: &lt;3 mmol/L,high: &gt;5.5 mmol/L),sodium (low: &lt;130 mmol/L,high: &gt;150 mmol/L),total bilirubin(high :&gt;= 1.5xULN). Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High),or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the participants has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, To low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, To Normal or no Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, To low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, To low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, To low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, To low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria</title>
        <description>Hematology parameters with PCI ranges: hematocrit (high: &gt;0.54 percentage of red blood cells), hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8*giga cells per liter [10^9/L]), total neutrophil count (low: &lt;1.5*10^9/L), platelet count (low: &lt;100*10^9/L and high: &gt;550*10^9/L), and while blood cell (WBC) count (low: &lt;3*10^9/L and high: &gt;20*10^9/L). Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 67</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O6">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria</title>
          <description>Hematology parameters with PCI ranges: hematocrit (high: &gt;0.54 percentage of red blood cells), hemoglobin (high: &gt;180 grams per liter [g/L]), lymphocytes (low: &lt;0.8*giga cells per liter [10^9/L]), total neutrophil count (low: &lt;1.5*10^9/L), platelet count (low: &lt;100*10^9/L and high: &gt;550*10^9/L), and while blood cell (WBC) count (low: &lt;3*10^9/L and high: &gt;20*10^9/L). Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the &quot;To Normal or No Change&quot; category. Participants are counted twice if the subject has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemotocrit, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, To Normal or No change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, To Normal or No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, To Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, To Normal or no Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, To High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Number of Participants With Abnormal Urinalysis Dipstick Results</title>
        <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed abnormal data for red blood cells (RBC): 1-9 High potential field (HPF) and WBC: 1-9/ HPF; WBC: 10-50/HPF has been presented.</description>
        <time_frame>Day 2 (post-dose)</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O6">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Urinalysis Dipstick Results</title>
          <description>Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed abnormal data for red blood cells (RBC): 1-9 High potential field (HPF) and WBC: 1-9/ HPF; WBC: 10-50/HPF has been presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC 1-9/ HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC 1-9/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC 10-50/HPF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in IR Formulation</title>
        <description>SBP and DBP were measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in IR Formulation</title>
          <description>SBP and DBP were measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in SBP and DBP in MR Formulation</title>
        <description>SBP and DBP were measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in SBP and DBP in MR Formulation</title>
          <description>SBP and DBP were measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Day1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="5.76"/>
                    <measurement group_id="O2" value="-7.9" spread="6.82"/>
                    <measurement group_id="O3" value="-7.3" spread="8.57"/>
                    <measurement group_id="O4" value="-4.6" spread="8.38"/>
                    <measurement group_id="O5" value="-3.4" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="8.07"/>
                    <measurement group_id="O2" value="-6.9" spread="8.32"/>
                    <measurement group_id="O3" value="-2.4" spread="10.07"/>
                    <measurement group_id="O4" value="-0.09" spread="13.02"/>
                    <measurement group_id="O5" value="-1.3" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="7.55"/>
                    <measurement group_id="O2" value="-10.3" spread="8.69"/>
                    <measurement group_id="O3" value="-2.8" spread="8.87"/>
                    <measurement group_id="O4" value="-6.8" spread="5.72"/>
                    <measurement group_id="O5" value="-2.3" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Day3, 48 hours,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="9.29"/>
                    <measurement group_id="O2" value="-5.3" spread="7.15"/>
                    <measurement group_id="O3" value="-1.7" spread="8.87"/>
                    <measurement group_id="O4" value="-4.2" spread="7.74"/>
                    <measurement group_id="O5" value="2.8" spread="7.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="5.67"/>
                    <measurement group_id="O2" value="-5.3" spread="5.70"/>
                    <measurement group_id="O3" value="-6.1" spread="3.53"/>
                    <measurement group_id="O4" value="-6.9" spread="5.11"/>
                    <measurement group_id="O5" value="-2.3" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="7.46"/>
                    <measurement group_id="O2" value="-8.3" spread="5.35"/>
                    <measurement group_id="O3" value="-5.7" spread="5.14"/>
                    <measurement group_id="O4" value="-5.9" spread="6.35"/>
                    <measurement group_id="O5" value="-5.3" spread="7.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="6.30"/>
                    <measurement group_id="O2" value="-10.0" spread="4.15"/>
                    <measurement group_id="O3" value="-6.6" spread="5.76"/>
                    <measurement group_id="O4" value="-4.5" spread="4.93"/>
                    <measurement group_id="O5" value="-0.4" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Day3, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="6.26"/>
                    <measurement group_id="O2" value="-3.7" spread="4.71"/>
                    <measurement group_id="O3" value="-2.1" spread="7.33"/>
                    <measurement group_id="O4" value="-2.4" spread="5.20"/>
                    <measurement group_id="O5" value="-1.1" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Heart Rate in IR Formulation</title>
        <description>Heart rate was measured in a semi-supine position after 5 minutes of rest of participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Heart Rate in IR Formulation</title>
          <description>Heart rate was measured in a semi-supine position after 5 minutes of rest of participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Heart Rate in MR Formulation</title>
        <description>Heart rate was measured in a semi-supine position after 5 minutes of rest of participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Heart Rate in MR Formulation</title>
          <description>Heart rate was measured in a semi-supine position after 5 minutes of rest of participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="7.22"/>
                    <measurement group_id="O2" value="-6.1" spread="7.78"/>
                    <measurement group_id="O3" value="5.8" spread="6.87"/>
                    <measurement group_id="O4" value="3.1" spread="7.33"/>
                    <measurement group_id="O5" value="-1.3" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="9.62"/>
                    <measurement group_id="O2" value="6.1" spread="9.79"/>
                    <measurement group_id="O3" value="9.8" spread="7.72"/>
                    <measurement group_id="O4" value="3.4" spread="10.19"/>
                    <measurement group_id="O5" value="8.8" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="7.36"/>
                    <measurement group_id="O2" value="-4.7" spread="8.72"/>
                    <measurement group_id="O3" value="2.4" spread="8.56"/>
                    <measurement group_id="O4" value="1.6" spread="9.21"/>
                    <measurement group_id="O5" value="-2.4" spread="4.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="11.39"/>
                    <measurement group_id="O2" value="0.4" spread="8.58"/>
                    <measurement group_id="O3" value="3.8" spread="5.67"/>
                    <measurement group_id="O4" value="4.7" spread="9.71"/>
                    <measurement group_id="O5" value="7.3" spread="7.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Respiration Rate in IR Formulation</title>
        <description>Respiratory rate was measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Respiration Rate in IR Formulation</title>
          <description>Respiratory rate was measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Respiration Rate in MR Formulation</title>
        <description>Respiratory rate was measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
        <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Respiration Rate in MR Formulation</title>
          <description>Respiratory rate was measured in a semi-supine position after 5 minutes of rest of the participant. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population. Only those participants with data available at the specified time points were analyzed (represented by n=X in category titles).</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours; n=16, 16, 12, 16, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.89"/>
                    <measurement group_id="O2" value="2.5" spread="2.58"/>
                    <measurement group_id="O3" value="2.8" spread="2.29"/>
                    <measurement group_id="O4" value="2.0" spread="2.13"/>
                    <measurement group_id="O5" value="0.0" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours; n=15, 16, 12, 16, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.68"/>
                    <measurement group_id="O2" value="0.8" spread="1.94"/>
                    <measurement group_id="O3" value="2.2" spread="2.25"/>
                    <measurement group_id="O4" value="0.9" spread="2.14"/>
                    <measurement group_id="O5" value="2.1" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours; n=16, 16, 12, 16, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.93"/>
                    <measurement group_id="O2" value="0.9" spread="2.58"/>
                    <measurement group_id="O3" value="1.9" spread="2.43"/>
                    <measurement group_id="O4" value="2.2" spread="1.64"/>
                    <measurement group_id="O5" value="0.9" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 48 hours; n=16, 16, 12, 16, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.00"/>
                    <measurement group_id="O2" value="0.4" spread="1.79"/>
                    <measurement group_id="O3" value="4.0" spread="2.37"/>
                    <measurement group_id="O4" value="0.7" spread="1.99"/>
                    <measurement group_id="O5" value="-0.4" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Body Temperature in IR Formulation</title>
        <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Body Temperature in IR Formulation</title>
          <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Change From Baseline in Body Temperature in MR Formulation</title>
        <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
        <time_frame>Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24 hours, Day 3: 48 hours</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Change From Baseline in Body Temperature in MR Formulation</title>
          <description>Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.</description>
          <population>Safety Population.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.216"/>
                    <measurement group_id="O2" value="0.14" spread="0.190"/>
                    <measurement group_id="O3" value="-0.03" spread="0.107"/>
                    <measurement group_id="O4" value="-0.06" spread="0.141"/>
                    <measurement group_id="O5" value="-0.04" spread="0.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.180"/>
                    <measurement group_id="O2" value="0.15" spread="0.266"/>
                    <measurement group_id="O3" value="0.11" spread="0.162"/>
                    <measurement group_id="O4" value="-0.04" spread="0.150"/>
                    <measurement group_id="O5" value="0.24" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.188"/>
                    <measurement group_id="O2" value="0.12" spread="0.148"/>
                    <measurement group_id="O3" value="0.06" spread="0.151"/>
                    <measurement group_id="O4" value="0.05" spread="0.175"/>
                    <measurement group_id="O5" value="0.08" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.163"/>
                    <measurement group_id="O2" value="0.01" spread="0.247"/>
                    <measurement group_id="O3" value="0.04" spread="0.156"/>
                    <measurement group_id="O4" value="0.01" spread="0.178"/>
                    <measurement group_id="O5" value="0.07" spread="0.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in IR Formulation</title>
        <description>Single 12-lead ECGs were obtained using an automated ECG machine that calculated PR, QRS, QT and Corrected QT (QTc) intervals. ECG measurements were performed in a semi-supine or supine position. Number of participants with abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 67</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: IR 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in IR Formulation</title>
          <description>Single 12-lead ECGs were obtained using an automated ECG machine that calculated PR, QRS, QT and Corrected QT (QTc) intervals. ECG measurements were performed in a semi-supine or supine position. Number of participants with abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal-Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in MR Formulation</title>
        <description>Single 12-lead ECGs were obtained using an automated ECG machine that calculated PR, QRS, QT and Corrected QT (QTc) intervals. ECG measurements were performed in a semi-supine or supine position. Number of participants with abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for worst-case post-Baseline has been reported.</description>
        <time_frame>Up to Day 67</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: MR-12h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
          </group>
          <group group_id="O2">
            <title>Part A: MR-18h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
          </group>
          <group group_id="O3">
            <title>Part A: MR-12h 240 mg Fed (High-Fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
          </group>
          <group group_id="O4">
            <title>Part A: MR-18h 240 mg Fed (High-fat)</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
          </group>
          <group group_id="O5">
            <title>Part A: MR-16h 240 mg Fasted</title>
            <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Number of Participants With Abnormal Electrocardiogram (ECG) Findings in MR Formulation</title>
          <description>Single 12-lead ECGs were obtained using an automated ECG machine that calculated PR, QRS, QT and Corrected QT (QTc) intervals. ECG measurements were performed in a semi-supine or supine position. Number of participants with abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for worst-case post-Baseline has been reported.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal-Not Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal - Clinically Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious AEs and SAEs were collected up to Day 67 for Part A and up to Day 68 for Part B</time_frame>
      <desc>Non-serious AEs and SAEs were collected in Safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: IR 240 mg Fasted</title>
          <description>Participants received a single oral dose of 240 mg (8x30mg) GSK2982772 IR tablet in a fasted state</description>
        </group>
        <group group_id="E2">
          <title>Part A: MR-12h 240 mg Fasted</title>
          <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet in fasted state</description>
        </group>
        <group group_id="E3">
          <title>Part A: MR-18h 240mg Fasted</title>
          <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet in fasted state</description>
        </group>
        <group group_id="E4">
          <title>Part A: MR-12h 240mg Fed (High-Fat)</title>
          <description>Participants received a single oral dose of 240 mg GSK2982772 MR-12h tablet after a high fat meal in fed state</description>
        </group>
        <group group_id="E5">
          <title>Part A: MR-18h 240mg Fed (High-Fat)</title>
          <description>Participants received a single oral dose of 240 mg GSK2982772 MR-18h tablet after high fat meal in fed state</description>
        </group>
        <group group_id="E6">
          <title>Part A: MR-16h 240mg Fasted</title>
          <description>Participants received a single oral dose of 240 mg GSK2982772 MR-16h tablet in fasted state</description>
        </group>
        <group group_id="E7">
          <title>Part B: MR-16h 480mg Fasted</title>
          <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
        </group>
        <group group_id="E8">
          <title>Part B: MR-16h 480 mg Fed (Std)</title>
          <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after a standard breakfast (fed state)</description>
        </group>
        <group group_id="E9">
          <title>Part B: MR-16h 480mg Fed (High-fat)</title>
          <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) tablet after high fat breakfast (fed state)</description>
        </group>
        <group group_id="E10">
          <title>Part B: MR-16h 480mg Fed (High-Fat) (Enteric Coated)</title>
          <description>Participants received a single oral dose of 480 mg GSK2982772 MR-16h (80% release in 16 hours) enteric coated tablet after a high fat breakfast (fed state)</description>
        </group>
        <group group_id="E11">
          <title>Part B: MR-16h 960mg Fasted</title>
          <description>Participants received a single oral dose of 960 mg GSK2982772 MR-16h (80% release in 16 hours) tablet in fasted state</description>
        </group>
        <group group_id="E12">
          <title>Part B: MR-16h 120mg Fasted</title>
          <description>Participants received 120 mg GSK2982772 MR-16 h (80% release in 16 hours) tablet in fasted state</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

